- $1.05bn
- $2.97bn
- $3.26bn
- 84
- 97
- 61
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.51 | ||
| PEG Ratio (f) | 1.66 | ||
| EPS Growth (f) | 5.4% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.46 | ||
| Price to Sales | 0.32 | ||
| EV to EBITDA | 4.68 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.59% | ||
| Return on Equity | 5.46% | ||
| Operating Margin | 7.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,056.39 | 2,454.53 | 2,970.59 | 3,200.18 | 3,260.97 | 3,267.35 | 3,425.28 | 43.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -56.64 | n/a | n/a | +0.25 | +17.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adapthealth Corp. is a provider of patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies, and related services. The Company's Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. Its Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. Its Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. Its Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities.
Directors
- Richard Barasch NEC (67)
- Joshua Parnes PRE (43)
- Stephen Griggs CEO (63)
- Jason Clemens CFO (43)
- Albert Prast CTO (60)
- Frank Mullen CAO (51)
- Anton Hie VPR
- Christopher Joyce GCN (57)
- Daniel Bunting OTH (59)
- Shaw Rietkerk OTH (46)
- Greg Belinfanti IND (41)
- Terence Connors IND (66)
- Bradley Coppens IND (39)
- Theodore Lundberg IND (46)
- Susan Weaver IND (60)
- David Williams IND (48)
- Dale Wolf IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 22nd, 2017
- Public Since
- February 21st, 2018
- No. of Shareholders
- 37
- No. of Employees
- 10,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 134,867,011
- Address
- 220 W Germantown Pike Ste 250, PLYMOUTH MEETING, 19462
- Web
- https://adapthealth.com/investor-relations/
- Phone
- +1 6106306357
- Auditors
- KPMG LLP
Upcoming Events for AHCO
Adapthealth Corp Annual Shareholders Meeting
Q2 2025 Adapthealth Corp Earnings Release
Similar to AHCO
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Alpha Tau Medical
NASDAQ Capital Market
FAQ
What is the Adapthealth share price?
As of Today at 19:04 UTC, shares in Adapthealth are trading at $7.79. This share price information is delayed by 15 minutes.
How has the Adapthealth share price performed this year?
Shares in Adapthealth last closed at $7.79 and the price had moved by -17.39% over the past 365 days. In terms of relative price strength the Adapthealth share price has underperformed the S&P500 Index by -22.32% over the past year.
What are the analyst and broker recommendations for Adapthealth?
The overall consensus recommendation for Adapthealth is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Adapthealth dividend yield?
Adapthealth does not currently pay a dividend.
Does Adapthealth pay a dividend?
Adapthealth does not currently pay a dividend.
When does Adapthealth next pay dividends?
Adapthealth does not currently pay a dividend.
How do I buy Adapthealth shares?
To buy shares in Adapthealth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adapthealth?
As of the previous close price of $7.79, shares in Adapthealth had a market capitalisation of $1.05bn.
Where are Adapthealth shares listed?
Here are the trading details for Adapthealth:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AHCO
What kind of share is Adapthealth?
Based on an overall assessment of its quality, value and momentum Adapthealth is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adapthealth share price forecast for 2025?
The analyst consensus target price for shares in Adapthealth is $13.00. That is 66.88% above the last closing price of $7.79.
Analysts covering Adapthealth currently have a consensus Earnings Per Share (EPS) forecast of $0.87 for the next financial year.
Find out moreWhat is the trend in the Adapthealth share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adapthealth. Over the past six months, its share price has underperformed the S&P500 Index by -21.52%.
As of the last closing price of $7.79, shares in Adapthealth were trading -23.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adapthealth PE Ratio?
The Adapthealth PE ratio based on its reported earnings over the past 12 months is 8.51. The shares last closed at $7.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adapthealth?
Adapthealth's management team is headed by:
- Richard Barasch - NEC
- Joshua Parnes - PRE
- Stephen Griggs - CEO
- Jason Clemens - CFO
- Albert Prast - CTO
- Frank Mullen - CAO
- Anton Hie - VPR
- Christopher Joyce - GCN
- Daniel Bunting - OTH
- Shaw Rietkerk - OTH
- Greg Belinfanti - IND
- Terence Connors - IND
- Bradley Coppens - IND
- Theodore Lundberg - IND
- Susan Weaver - IND
- David Williams - IND
- Dale Wolf - IND